Showing results (211-220 of 235) with videos related to
Sort By:
Pageof 24
International Journal of Cancer|June 2, 2025
Mass cytometric detection of homologous recombination proficiency in circulating tumor cells to predict chemoresistance of metastatic breast cancer patientsKathrin Niedermayer, Henning Schäffler, Georgios Vlachos, et al.Journal of the National Cancer Institute|May 17, 2014
Circulating tumor cells predict survival in early average-to-high risk breast cancer patientsBrigitte Rack, Christian Schindlbeck, Julia Jückstock, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 7, 2016
Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast CancerWolfgang J Janni, Brigitte Rack, Leon W M M Terstappen, et al.Clinical Breast Cancer|July 19, 2018
Use of Granulocyte-colony Stimulating Factor During Chemotherapy and Its Association With CA27.29 and Circulating Tumor Cells-Results From the SUCCESS A TrialPhilip Hepp, Peter A Fasching, Matthias W Beckmann, et al.BMC Cancer|July 9, 2016
Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trialJulia Jueckstock, Brigitte Rack, Thomas W P Friedl, et al.Clinical Breast Cancer|June 19, 2023
Association Between Obesity and Circulating Tumor Cells in Early Breast Cancer PatientsMarie Tzschaschel, Thomas W P Friedl, Fabienne Schochter, et al.Human Molecular Genetics|October 21, 2019
BRCA1 mislocalization leads to aberrant DNA damage response in heterozygous ABRAXAS1 mutation carrier cellsMuthiah Bose, Juliane Sachsenweger, Niina Laurila, et al.Archives of Gynecology and Obstetrics|September 11, 2015
Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study programAmelie Schramm, Thomas W P Friedl, Fabienne Schochter, et al.International Journal of Molecular Sciences|September 13, 2025
Is Radiographic Aftercare Obsolete? How Testing Positive for ctDNA Can Be a Precedent for Late Relapse, Even in Low-Risk Hormone-Receptor-Positive Breast CancerKerstin Pfister, Sophia Huesmann, Angelina Fink, et al.ESMO Open|November 28, 2021
Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study programV Müller, M Banys-Paluchowski, T W P Friedl, et al.Pageof 24